Iron in Friedreich Ataxia: A Central Role in the Pathophysiology or an Epiphenomenon?
AbstractFriedreich ataxia is a neurodegenerative disease with an autosomal recessive inheritance. In most patients, the disease is caused by the presence of trinucleotide GAA expansions in the first intron of the frataxin gene. These expansions cause the decreased expression of this mitochondrial protein. Many evidences indicate that frataxin deficiency causes the deregulation of cellular iron homeostasis. In this review, we will discuss several hypotheses proposed for frataxin function, their caveats, and how they could provide an explanation for the deregulation of iron homeostasis found in frataxin-deficient cells. We will also focus on the potential mechanisms causing cellular dysfunction in Friedreich Ataxia and on the potential use of the iron chelator deferiprone as a therapeutic agent for this disease. View Full-Text
Share & Cite This Article
Alsina, D.; Purroy, R.; Ros, J.; Tamarit, J. Iron in Friedreich Ataxia: A Central Role in the Pathophysiology or an Epiphenomenon? Pharmaceuticals 2018, 11, 89.
Alsina D, Purroy R, Ros J, Tamarit J. Iron in Friedreich Ataxia: A Central Role in the Pathophysiology or an Epiphenomenon? Pharmaceuticals. 2018; 11(3):89.Chicago/Turabian Style
Alsina, David; Purroy, Rosa; Ros, Joaquim; Tamarit, Jordi. 2018. "Iron in Friedreich Ataxia: A Central Role in the Pathophysiology or an Epiphenomenon?" Pharmaceuticals 11, no. 3: 89.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.